Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and ...
Merck announces positive Phase 3 trial results for GARDASIL 9, showing reduced HPV-related anogenital persistent infection in Japanese males ages 16-26. The vaccine met primary and secondary endpoints, with plans to share data with regulatory authorities in Japan and other countries to support licensure for use in males.
Related Clinical Trials
Reference News
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and ...
Merck announces positive Phase 3 trial results for GARDASIL 9, showing reduced HPV-related anogenital persistent infection in Japanese males ages 16-26. The vaccine met primary and secondary endpoints, with plans to share data with regulatory authorities in Japan and other countries to support licensure for use in males.